Merck

Variational AI is a biotechnology company that leverages advanced machine learning techniques to efficiently generate novel compounds optimized for multiple therapeutic properties. Focused on drug discovery, the company aims to address key challenges in the pharmaceutical industry, particularly those related to drug attrition and the likelihood of clinical success. Variational AI specializes in developing selective kinase inhibitors for solid tumor indications and has plans to expand its target classes. By collaborating with leading biopharmaceutical partners and building an internal pipeline, the company enables faster identification of drug-like molecules that are potent, selective, safe, and synthesizable. Its innovative approach aims to reduce the time necessary for molecular optimization and enhance the success rates of drug development.

HD is a healthcare and surgery marketplace, powering over 1,500+ healthcare providers including some of the biggest hospitals. HD connects patients to hospitals, clinics, operating rooms, and surgeons while offering healthcare financing solutions to increase access to affordable care and surgeries. To date, over 250,000 patients have benefited from more accessible and affordable healthcare and surgeries through the company's platform.

Evaxion Biotech A/S is a clinical-stage biotechnology company focused on leveraging artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer and infectious diseases. Utilizing its proprietary AI-immunology technology, the company is advancing a diverse pipeline of product candidates, which includes three patient-specific cancer immunotherapies, two of which are currently in Phase I/IIa clinical development. In addition to its cancer therapies, Evaxion is also working on a portfolio of vaccines aimed at preventing bacterial and viral infections, with one program in preclinical development targeting Methicillin-resistant Staphylococcus aureus and related skin and soft tissue infections. The company's innovative approach aims to enhance treatment efficacy for patients with unmet medical needs.

Personalis, Inc. is a cancer genomics company based in Menlo Park, California, that specializes in genomic sequencing and data analysis services aimed at advancing personalized cancer therapies. Established in 2011, the company offers a range of products, including the NeXT Platform, which provides critical data for the development of personalized therapies, therapy selection, and diagnostics. Additionally, Personalis provides a liquid biopsy assay that examines various human genes to enhance cancer treatment strategies. The company's services support biopharmaceutical clients, universities, non-profit organizations, diagnostics companies, and government agencies, facilitating the creation of safer and more effective precision cancer therapies and immunotherapies. Personalis is recognized for its integration of sequencing technology and data interpretation, contributing to a comprehensive understanding of tumor biology and its interaction with the immune system.

Modifi Biosciences specializes in direct DNA modification and the development of innovative cancer therapeutics. The company focuses on a unique strategy that involves altering tumor DNA to make cancer cells irreparable, while ensuring that healthy cells remain unharmed. This approach allows researchers to challenge and advance traditional methods of oncology drug development, potentially leading to more effective treatments for a variety of cancers. By exploiting DNA defects found in cancer cells, Modifi Biosciences aims to contribute significantly to the field of cancer research and therapy.

Ash is a leading at-home health testing platform expanding care to reach those most in need. Working closely with our partners, we tailor end-to-end testing solutions that meet the unique needs of any health organization’s population. Our strength comes from our unmatched understanding of people—whether that means learning the best ways to reach them or innovating a new way to keep them connected and cared for. We use our deep knowledge to develop field-tested best practices that engage hard-to-reach patients and members where they are. Because when people come first, better health outcomes are possible for all.

Qure.ai Technologies Private Limited specializes in developing artificial intelligence software for the healthcare sector, focusing on medical imaging to enhance disease diagnosis from radiology and pathology images. Founded in 2016 and headquartered in Mumbai, India, with a presence in New York, the company offers tools such as qXR, which automates chest X-ray interpretation to identify abnormal findings, including signs of tuberculosis. Qure.ai also provides qER, which assists in triaging critical head CT scans and offers tools for monitoring traumatic brain injury and reporting. By leveraging deep learning solutions, Qure.ai aims to improve the accuracy of diagnoses and make healthcare more affordable and accessible, ultimately allowing healthcare professionals to dedicate more time to patient care.

CargoSense, Inc. is a Software-as-a-Service (SaaS) company based in Reston, Virginia, that specializes in providing logistics oversight solutions for supply chain networks. Founded in 2012, CargoSense offers a range of collaborative supply chain software and applications tailored to various industries, including transportation, life sciences, and food and beverage. Its suite of products includes CARGOSENSE SUPPLY for cold chain oversight, CARGOSENSE FRESH for compliance with regulations, CARGOSENSE CLINICAL for monitoring clinical trials, and CARGOSENSE CONTROL for real-time load sensor management. The company utilizes advanced data analytics, cloud-based storage, and Bluetooth sensors to deliver comprehensive visibility into shipment conditions, including temperature, humidity, and other environmental factors. This enables customers to ensure product quality, comply with regulatory standards, and reduce shipping costs while minimizing product loss. CargoSense's innovative approach effectively transforms logistics data into actionable insights, enhancing operational efficiency and reliability across diverse sectors.

Eyebiotech is a vision treatment company that develops products to preserve, repair, and improve eyesight. The firm guards against sight-threatening eye disorders and developed the first anti-vascular endothelial growth factor medication for patients with age-related macular degeneration, allowing those with eye ailments to regain their eyesight.

Friends of Puerto Rico is a nonpartisan, non-profit social impact group that advocates for economic growth. and education through result-oriented entrepreneurial ventures centered on sustainability and self-sufficiency.

Atropos Health, founded in 2019 and based in Palo Alto, California, specializes in developing a digital prognostogram platform that transforms health data into usable real-world evidence. The Atropos Evidence Platform integrates electronic medical record (EMR) data to generate digital evidence tailored to individual patient outcomes. It serves a diverse clientele, including healthcare organizations, life science companies, and researchers, by enabling them to derive value from previously isolated EMR data. This cloud-based platform addresses evidence gaps from bench to bedside, enhances clinical outcomes through data-driven care, and accelerates research efforts in the medical field.

N-Power Medicine is a biotechnology company focused on advancing drug development and clinical research, particularly within the field of oncology. The company operates a network of community oncology centers staffed with qualified professionals who assist in identifying suitable patients for research studies. This approach not only accelerates the pace of clinical trials but also aims to enhance the diversity of patient populations involved in these studies. By facilitating faster and more efficient research processes, N-Power Medicine aims to support pharmaceutical companies and researchers in their efforts to innovate and improve cancer treatment options.

Transcarent is a consumer-directed health and care platform designed for employees of self-insured employers and their families. The company utilizes a blend of software, technology, and data science to provide consumers with unbiased information and trusted guidance. By connecting users to a network of high-value healthcare providers and services, Transcarent aims to empower individuals to make informed choices and achieve better health outcomes while navigating the complexities of the healthcare system. This approach fosters transparency and cost-effective decision-making, addressing a wide range of healthcare challenges faced by consumers today.

Abceutics, headquartered in Buffalo, New York, is a biopharmaceutical company dedicated to developing innovative therapies for unmet medical needs.

Baseimmune is a biotech startup focused on developing next-generation vaccines. The company has created a platform for pathogen analysis that facilitates the design of antigens and vaccines. Utilizing innovative technology, Baseimmune's platform generates antigens through a sophisticated level of informatics, which addresses emerging and challenging pathogens. This approach allows healthcare providers to maintain vaccine efficacy, even in the face of pathogen mutations. By prioritizing advanced solutions in vaccine development, Baseimmune aims to enhance public health responses to infectious diseases.

Evaxion Biotech A/S is a clinical-stage biotechnology company focused on leveraging artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer and infectious diseases. Utilizing its proprietary AI-immunology technology, the company is advancing a diverse pipeline of product candidates, which includes three patient-specific cancer immunotherapies, two of which are currently in Phase I/IIa clinical development. In addition to its cancer therapies, Evaxion is also working on a portfolio of vaccines aimed at preventing bacterial and viral infections, with one program in preclinical development targeting Methicillin-resistant Staphylococcus aureus and related skin and soft tissue infections. The company's innovative approach aims to enhance treatment efficacy for patients with unmet medical needs.

Harpoon Therapeutics, Inc. is a clinical-stage immunotherapy company based in South San Francisco, California, focused on developing a novel class of T cell engagers to harness the body's immune system for treating cancer and other diseases. The company utilizes its proprietary TriTAC (Tri-specific T cell Activating Construct) platform to create engineered proteins that direct T cells to target and kill cells expressing specific antigens. Harpoon's lead product candidate, HPN424, is currently undergoing Phase I clinical trials for metastatic castration-resistant prostate cancer. Additionally, the company is advancing other candidates, including HPN536, which is in Phase I/IIa trials for ovarian cancer and MSLN-expressing tumors, as well as HPN217 for multiple myeloma and HPN328 for small cell lung cancer. Harpoon Therapeutics was founded in 2015 and is committed to addressing unmet medical needs in oncology through innovative therapies.

Unnatural Products Inc. is a biotechnology company based in Santa Cruz, California, focused on drug discovery through innovative technology. Founded in 2016, the company specializes in designing and developing a platform that utilizes artificial intelligence and computational biology techniques to create macrocyclic peptides. These peptides target intracellular protein interactions, addressing drug targets that are typically considered undruggable. By harnessing machine learning to optimize chemical synthesis, Unnatural Products aims to accelerate the drug discovery process, offering potential therapeutic strategies for a wide range of medical conditions. Through its unique approach, the company seeks to pioneer new treatments where traditional methods have fallen short.

Culmination Bio is a startup that is developing a disease-independent patient data intelligence platform.

Caraway Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, that focuses on developing innovative treatments for neurodegenerative diseases by modulating mitophagy and autophagy. The company aims to address the degradation of toxic cellular components, which is a key factor in various neurodegenerative conditions, including Parkinson's disease and amyotrophic lateral sclerosis. By leveraging an understanding of critical neural pathways, Caraway Therapeutics seeks to discover and develop novel small molecules that can restore cellular balance and improve lysosomal function. Founded in 2018 and initially known as Rheostat Therapeutics, Inc., the company rebranded in 2019 to reflect its commitment to finding effective therapies for patients affected by these debilitating diseases.

AeroSafe Global is a U.S.-based company that develops and manufactures aerogels for thermal insulation, primarily serving the biopharmaceutical industry. Its products ensure reliable, sustainable, and simple temperature-sensitive supply chain solutions. AeroSafe Global specializes in cold-chain services, providing customized packaging, logistics, and operational services to prevent any temperature excursions during transportation of biomedical and pharmaceutical products.

Octave is a clinical platform developer focused on transforming the care landscape for multiple sclerosis and other neurodegenerative diseases. The company creates a platform that generates, analyzes, and integrates data to improve patient outcomes and reduce overall healthcare costs. By optimizing medication usage and healthcare services, Octave aims to enhance the efficiency of the pharmaceutical industry throughout the entire lifecycle of drug development, which includes discovery, clinical trials, and post-marketing phases. Their approach utilizes real-world evidence to inform decision-making, ultimately striving to set a new standard in multiple sclerosis care.

Prognos Health is a health tech company focused on healthcare analytics, offering a platform called prognosFACTOR. This innovative platform can quickly query billions of lab and health records from over 325 million de-identified patients, providing answers to clinically relevant healthcare questions in a fraction of the time traditionally required. Prognos Health allows clients to access HIPAA-compliant, patient-centric healthcare data through the Prognos Marketplace, facilitating a range of applications such as cohort design, patient journey studies, and health outcomes analysis. The company's clientele includes 25 of the top 30 pharmaceutical manufacturers and three of the top five health payers, highlighting its significant role in empowering precise decision-making throughout the healthcare landscape.

Prometheus Biosciences, established in 1995 and headquartered in San Diego, California, specializes in developing and commercializing innovative pharmaceutical and diagnostic products. The company's portfolio includes tests that enable physicians to provide personalized patient care, such as monitoring drug and anti-drug antibody levels, diagnosing and prognosticating inflammatory bowel disease (IBD), and detecting celiac disease and lactose intolerance. Prometheus also offers therapeutic products like Entocort EC for treating Crohn's disease and has agreements to develop and market other drugs. The company's commitment to innovation positions it as a leader in precision healthcare, particularly in gastroenterology.

Mamotest is a technology-driven company focused on improving breast cancer outcomes through early diagnosis and patient guidance. By leveraging artificial intelligence, Mamotest has developed a collaborative platform that democratizes access to screening and diagnosis, facilitating an efficient path to treatment. The company's innovative approach integrates telediagnosis and ensures complete traceability of the patient journey, aiming to transition healthcare from a reactive model to one that prioritizes prevention and health maintenance. Operating in Spain, Argentina, and Mexico, Mamotest's mission is to significantly reduce breast cancer mortality rates, thereby enhancing the overall quality of care for patients.

Pragma Bio is a biotechnology company that focuses on developing microbiome-based therapeutics for cancer and autoimmune diseases. Founded in 2018 in Millbrae, California, by Peter McCaffrey, Kovi Bessoff, Ayin Vala, and Kareem Barghouti, the company utilizes proprietary genomic sequencing, artificial intelligence, and synthetic biology techniques to discover biomarkers and therapeutics for complex immunologic disorders. Pragma Bio's platform aggregates both public and private data to create a comprehensive microbiome database, enhancing the ability to identify connections between diverse biological data. This approach not only aids in the discovery of novel biomarkers for patient risk stratification and clinical outcome prediction but also enables the identification of small molecules derived from human-associated bacteria. By leveraging real-world data and advanced analytical processes, Pragma Bio aims to streamline drug discovery and deliver innovative medicines more efficiently and cost-effectively, particularly in relation to the gut-immune axis.

IndyGeneUS AI is a Black-Owned and Service-Disabled Veteran-Owned Small Business specializing in genomics. The company is developing the world's largest blockchain-encrypted repository of clinical and genomic data specifically for indigenous and diasporic African populations. Utilizing proprietary technology, IndyGeneUS AI integrates multi-omics data, electronic healthcare records, and scientific literature to identify novel signature sequences, biomarkers, and polygenic risk scores. This extensive data repository aims to enhance disease prevention, detection, and drug discovery while promoting clinical disease management and precision health equity. By focusing on the unique genomic characteristics of these populations, the company seeks to improve the efficiency and quality of healthcare delivery.

TransVoyant, Inc. is an analytics company specializing in predictive solutions that leverage real-time big data streams to provide insights for various industries. Founded in 2011 and headquartered in Alexandria, Virginia, the company collects, cleanses, and analyzes over one trillion events daily from diverse sources, including IoT devices, sensors, and satellites. TransVoyant's offerings include Precise Predictive Intelligence (P2I) for behavior analysis and anomaly detection, Continuous Decision Intelligence (CDI) for industry-specific solutions, and Precise Predictive Logistics (P2L), which tracks the real-time behavior and location of various assets such as aircraft, vessels, and vehicles. The company's advanced machine learning algorithms empower Fortune 500 companies, niche consulting firms, and government agencies to anticipate and mitigate potential disruptions from factors like weather events, supply chain issues, and competitive behavior. TransVoyant has established strategic partnerships with major organizations to enhance its capabilities in delivering actionable insights.

Turbine Ltd, established in 2015 and headquartered in Budapest, Hungary, specializes in computational biology for cancer drug development. The company's core product is a predictive model that simulates cellular behavior, aiding in the discovery, preclinical testing, and development of cancer therapies. Turbine's platform leverages proprietary Simulated Cell technology and artificial intelligence to identify novel protein targets and precision biomarkers, ultimately enhancing the translation of research into effective patient treatments.

Imago BioSciences, Inc. is a clinical-stage biotechnology company based in Redwood City, California, founded in 2012. The company specializes in developing novel small molecule therapeutics aimed at treating hematologic diseases, including myelodysplastic syndromes, acute myelogenous leukemia, and other conditions associated with bone marrow failure. Central to its research is the enzyme lysine-specific demethylase 1 (LSD1), which is involved in the regulation of blood cell production. Imago BioSciences is focused on translating advanced scientific insights into transformative therapies that can alter the course of disease, thereby enhancing the quality and longevity of life for patients. Its lead product candidate, Bomedemstat, is an orally administered LSD1 inhibitor currently under evaluation for its potential to modify disease progression in patients with myeloproliferative neoplasms, a group of chronic bone marrow cancers.

Syapse, Inc. is a technology company that specializes in precision medicine through its innovative software platform, which aggregates and analyzes clinical, molecular, treatment, and outcomes data. Founded in 2008 and headquartered in San Francisco, California, with an additional office in Radnor, Pennsylvania, Syapse aims to enhance healthcare by providing actionable insights that support data-driven decision-making in precision oncology. The company operates the Syapse Learning Health Network, a global network that enables health systems and life sciences collaborators to share real-world cancer data. This network empowers healthcare organizations to collaborate effectively, ensuring that oncologists and decision-makers have access to comprehensive patient insights at the point of care, ultimately driving improved outcomes for cancer patients. Syapse has established strategic partnerships, including a collaboration with Pfizer, to further its mission of delivering personalized care based on robust real-world evidence.

Qure.ai Technologies Private Limited specializes in developing artificial intelligence software for the healthcare sector, focusing on medical imaging to enhance disease diagnosis from radiology and pathology images. Founded in 2016 and headquartered in Mumbai, India, with a presence in New York, the company offers tools such as qXR, which automates chest X-ray interpretation to identify abnormal findings, including signs of tuberculosis. Qure.ai also provides qER, which assists in triaging critical head CT scans and offers tools for monitoring traumatic brain injury and reporting. By leveraging deep learning solutions, Qure.ai aims to improve the accuracy of diagnoses and make healthcare more affordable and accessible, ultimately allowing healthcare professionals to dedicate more time to patient care.

CancerIQ is a precision health technology company focused on empowering healthcare providers to identify and manage patients at high risk for cancer. Its platform offers a comprehensive suite of tools, including predictive analytics and screening resources, to help clinicians accurately stratify patient risk and guide them toward appropriate genetic testing, screening, or treatment options. The platform features a robust content library of evidence-based guidelines and risk models, facilitating informed decision-making. Additionally, CancerIQ provides digital tools for genetic test ordering and patient management, aimed at enhancing patient education and engagement. By streamlining these processes, the company enables healthcare providers to improve patient outcomes and reduce the overall cost of care through early cancer detection.

Koneksa Health Inc. is a healthcare data analytics company that specializes in designing and developing software solutions for pharmaceutical and biotech firms. The company’s flagship product, Koneksa Compare, facilitates the collection, monitoring, and analysis of patient-generated data to support clinical studies and regulatory claims. By integrating emerging technologies such as bio-sensors, activity trackers, and mobile-based questionnaires, Koneksa enhances the accuracy and breadth of data that researchers can analyze, thereby minimizing subjective biases in clinical endpoints. Additionally, the platform provides a dashboard that offers electronic clinical outcome assessments and reminders for study participants. Established in 2013 and headquartered in New York, Koneksa also maintains a presence in London, United Kingdom, and is recognized for its contributions to improving the efficiency of drug development through innovative data analysis.

TagNTrac is an IoT platform that provides integrating multimode technologies typically hardware, software, and data to build solutions.

Verana Health, Inc. is a digital health company based in San Francisco, California, that specializes in transforming healthcare data into actionable insights. Founded in 2008 and formerly known as Digisight Technologies, the company connects healthcare providers with patients through innovative solutions. Its flagship product, SightBook, is a mobile application that enables users to test their vision and share results with their physicians in real-time, facilitating timely appointments and treatments. Verana Health manages data from over 20,000 healthcare providers and 70 electronic health record systems, leveraging its AI-enhanced platform, VeraQ™, to create a robust healthcare data ecosystem. By utilizing advanced analytics on curated datasets, Verana Health supports life sciences partners in improving clinical research and enhancing patient care outcomes.

Transcarent is a consumer-directed health and care platform designed for employees of self-insured employers and their families. The company utilizes a blend of software, technology, and data science to provide consumers with unbiased information and trusted guidance. By connecting users to a network of high-value healthcare providers and services, Transcarent aims to empower individuals to make informed choices and achieve better health outcomes while navigating the complexities of the healthcare system. This approach fosters transparency and cost-effective decision-making, addressing a wide range of healthcare challenges faced by consumers today.

PreciseDx is a specialized company focused on cancer risk stratification, providing patient-specific risk assessments through the analysis of morphological features. By leveraging artificial intelligence and its proprietary Morphology Feature Array™, PreciseDx develops disease-specific assays that enhance the understanding of a patient's risk profile and potential outcomes. This innovative approach allows clinical teams to gain valuable insights and actionable intelligence, facilitating more personalized treatment decisions. The company's expertise spans clinical modeling, patient phenotyping, image analysis, and the application of big data in real-world scenarios, ultimately aiming to improve patient outcomes and quality of life in cancer care and other diseases.

Verge Genomics is a biotechnology company focused on transforming drug discovery through the application of artificial intelligence. Founded by experts in machine learning and seasoned neuroscience drug developers, the company aims to leverage advancements in computational genomics and insights into neuroscience to discover innovative therapeutics for neurodegenerative diseases. Its drug discovery platform employs machine learning algorithms to analyze large datasets, identifying potential drug targets and predicting effective treatments. By accelerating the development of life-saving therapies, Verge Genomics seeks to enhance patient outcomes and reduce the costs associated with pharmaceutical development, thereby addressing critical challenges in the healthcare sector.

Tasso, Inc., established in 2012 and based in Seattle, Washington, specializes in manufacturing clinical-grade, at-home blood sample collection devices. Their innovative product allows patients to conveniently and painlessly collect their own blood at home using a simple, push-button mechanism, and then mail the samples to a qualified lab for analysis. This approach aims to enhance accessibility and comfort in blood-based diagnostics, reducing the need for clinic visits.

Octave is a clinical platform developer focused on transforming the care landscape for multiple sclerosis and other neurodegenerative diseases. The company creates a platform that generates, analyzes, and integrates data to improve patient outcomes and reduce overall healthcare costs. By optimizing medication usage and healthcare services, Octave aims to enhance the efficiency of the pharmaceutical industry throughout the entire lifecycle of drug development, which includes discovery, clinical trials, and post-marketing phases. Their approach utilizes real-world evidence to inform decision-making, ultimately striving to set a new standard in multiple sclerosis care.

Acceleron Pharma is a biopharmaceutical company based in Cambridge, Massachusetts, founded in 2003. It specializes in discovering, developing, and commercializing therapeutics to treat serious and rare diseases. Acceleron's portfolio includes luspatercept-aamt, marketed as REBLOZYL for treating anemia in adult patients with beta-thalassemia, and also under investigation for myelodysplastic syndromes and myelofibrosis. Additionally, the company is developing Sotatercept for pulmonary arterial hypertension and ACE-083 for Charcot-Marie-Tooth disease. Acceleron's research focuses on growth and differentiation factors that regulate cellular proliferation, differentiation, and survival in various tissue types. The company collaborates with other organizations to advance its therapeutic candidates.

Strata Oncology, Inc. is a precision oncology company focused on enhancing cancer care by facilitating access to precision medicine clinical trials and expediting drug approval processes. Based in Ann Arbor, Michigan, the company develops a comprehensive precision oncology platform that supports routine testing and efficient use of molecular data. Strata's offerings include The Strata Trial, a genomic testing program for systematic precision oncology implementation, and StrataNGS, a targeted assay for sequencing DNA and RNA from biopsies. Additionally, StrataPOINT integrates electronic medical record histories with molecular profiling to ensure eligible patients are tested and considered for trial enrollment. The company features a portfolio of pharma-sponsored therapeutic protocols, known as Strata Partnered Trials, aligned to specific biomarkers. Strata also operates The Strata Lab, a cancer sequencing facility, and maintains the Strata Precision Oncology Network, a collaborative entity aimed at promoting precision medicine initiatives. Formerly known as Strata Oncology Research, Inc., the company rebranded in 2016 and has been incorporated since 2015.

Transcarent is a consumer-directed health and care platform designed for employees of self-insured employers and their families. The company utilizes a blend of software, technology, and data science to provide consumers with unbiased information and trusted guidance. By connecting users to a network of high-value healthcare providers and services, Transcarent aims to empower individuals to make informed choices and achieve better health outcomes while navigating the complexities of the healthcare system. This approach fosters transparency and cost-effective decision-making, addressing a wide range of healthcare challenges faced by consumers today.

Antidote is a digital health company focused on accelerating and improving medical research. By combining proprietary technologies, data, and well-established business models, the company is transforming the way patients and researchers connect so that breakthroughs happen faster. Antidote was launched as TrialReach in 2010 and rebranded to Antidote in 2016. The company is based in the US and the UK.

PathAI, Inc. is a technology company that specializes in developing artificial intelligence solutions for pathology laboratories. Founded in 2016 and headquartered in Boston, Massachusetts, with an additional office in Austin, Texas, PathAI focuses on enhancing the accuracy and efficiency of cancer diagnosis and treatment. The company's platform employs machine and deep learning techniques to analyze large datasets, assisting pathologists in making rapid and precise diagnoses for patients. By addressing complex challenges in pathology, PathAI aims to facilitate personalized medicine and improve patient outcomes by identifying individuals who may benefit from innovative therapies.

Mamotest is a technology-driven company focused on improving breast cancer outcomes through early diagnosis and patient guidance. By leveraging artificial intelligence, Mamotest has developed a collaborative platform that democratizes access to screening and diagnosis, facilitating an efficient path to treatment. The company's innovative approach integrates telediagnosis and ensures complete traceability of the patient journey, aiming to transition healthcare from a reactive model to one that prioritizes prevention and health maintenance. Operating in Spain, Argentina, and Mexico, Mamotest's mission is to significantly reduce breast cancer mortality rates, thereby enhancing the overall quality of care for patients.

M2Gen, Corp. is a health informatics solutions company headquartered in Tampa, Florida, established in 2006 at the Moffitt Cancer Center. It specializes in advancing precision medicine through its integrated clinical and molecular data platform, which analyzes data to enhance patient care. M2Gen provides evidence-based solutions that help identify disease susceptibility, predict drug responses, and match patients with optimal therapies. The company operates the Total Cancer Care Protocol, a comprehensive approach that studies patients throughout their lifetime, and collaborates with leading cancer centers through the Oncology Research Information Exchange Network (ORIEN). Additionally, M2Gen offers the M2Gen Portfolio, which supports biopharmaceutical companies in discovering new targets and biomarkers, improving clinical trial design and enrollment, and facilitating long-term post-market analysis. M2Gen was formerly known as Moffitt Genetics Corporation, Inc. and rebranded in August 2017. It operates as a subsidiary of the H. Lee Moffitt Cancer Center & Research Institute.

Pandion Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Watertown, Massachusetts, focused on developing innovative therapeutics for patients with autoimmune diseases. The company’s lead product candidate, PT101, is an engineered interleukin-2 variant currently undergoing Phase 1a clinical trials for various autoimmune and inflammatory conditions, including moderate-to-severe ulcerative colitis and systemic lupus erythematosus. In addition to PT101, Pandion's pipeline includes PT627, a systemic PD-1 agonist in preclinical studies, and two bifunctional molecules, PT001 and PT002, designed to provide tissue-selective immunomodulation by targeting specific adhesion molecules in the gastrointestinal tract. Pandion employs a network-based approach to immune system conceptualization through its TALON drug design platform and collaborates with Astellas Pharma to develop locally acting immunomodulators for pancreatic autoimmune diseases. The company aims to create a new generation of therapeutics that offer enhanced efficacy and safety for the treatment of autoimmune and inflammatory diseases.

Absci is a drug and target discovery company that leverages deep learning AI and synthetic biology to enhance the therapeutic potential of proteins. Its Integrated Drug Creation Platform streamlines the process of identifying novel drug targets, discovering optimal biotherapeutic candidates, and generating the necessary cell lines for manufacturing. By combining biologic drug discovery and cell line development into a single, efficient workflow, Absci collaborates with biotech and pharmaceutical innovators to develop next-generation protein-based drugs. These innovations include Bionic Proteins, which feature nonstandard amino acids, and other unique drug designs that may be unattainable through conventional methods. Absci's mission is to facilitate the development of improved medicines by effectively translating innovative ideas into viable drugs.

OncoImmune, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapies for cancer and autoimmune diseases. Founded in 2000 and headquartered in Rockville, Maryland, the company has a diverse development portfolio that includes CD24Fc, a recombinant fusion protein designed for the prophylactic treatment of acute graft versus host disease, particularly in leukemia patients undergoing hematopoietic stem cell transplantation. Additionally, OncoImmune is developing sialidase inhibitors as a therapeutic strategy to prevent sepsis, ONC-392, a monoclonal antibody that aims to reduce immune-related toxicities while maintaining effective anti-tumor responses, and Echinomycin, a cyclic peptide formulation targeting acute myeloid leukemia. The company has completed a Phase II clinical trial for CD24Fc and is preparing to initiate a pivotal trial for this indication.

Zapata Computing, Inc. is a quantum software company that specializes in developing innovative computing solutions tailored for industrial and commercial applications. Founded in 2017 and headquartered in Boston, Massachusetts, with an additional office in Toronto, the company emerged from Harvard University and is driven by a team of scientists, including Alán Aspuru-Guzik. Zapata offers Orquestra, a software platform that enables the composition of quantum workflows using a YAML-compatible language, facilitating tasks across both quantum and classical hardware. Its solutions are hardware-agnostic and cater to various sectors, including finance, healthcare, pharmaceuticals, transportation, logistics, energy, and more. Equipped to address complex challenges, Zapata Computing focuses on simulation, optimization, and machine learning, helping enterprise organizations harness the power of quantum technology to enhance their operations.

Pragma Bio is a biotechnology company that focuses on developing microbiome-based therapeutics for cancer and autoimmune diseases. Founded in 2018 in Millbrae, California, by Peter McCaffrey, Kovi Bessoff, Ayin Vala, and Kareem Barghouti, the company utilizes proprietary genomic sequencing, artificial intelligence, and synthetic biology techniques to discover biomarkers and therapeutics for complex immunologic disorders. Pragma Bio's platform aggregates both public and private data to create a comprehensive microbiome database, enhancing the ability to identify connections between diverse biological data. This approach not only aids in the discovery of novel biomarkers for patient risk stratification and clinical outcome prediction but also enables the identification of small molecules derived from human-associated bacteria. By leveraging real-world data and advanced analytical processes, Pragma Bio aims to streamline drug discovery and deliver innovative medicines more efficiently and cost-effectively, particularly in relation to the gut-immune axis.

VelosBio, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing innovative antibody-drug conjugates (ADCs) to treat various hematological cancers and solid tumors. Established in 2017, the company specializes in therapies that target receptor tyrosine kinase-like orphan receptor 1 (ROR1), a protein present on many cancerous cells but absent in normal tissues, making it a promising target for cancer treatment. VelosBio's lead product, VLS-101, is an ROR1-directed ADC designed for patients with both hematologic and solid tumor malignancies. The company's approach aims to provide novel targeted therapies that can be utilized as monotherapy or in combination with other treatments across a wide array of cancer types.

Koneksa Health Inc. is a healthcare data analytics company that specializes in designing and developing software solutions for pharmaceutical and biotech firms. The company’s flagship product, Koneksa Compare, facilitates the collection, monitoring, and analysis of patient-generated data to support clinical studies and regulatory claims. By integrating emerging technologies such as bio-sensors, activity trackers, and mobile-based questionnaires, Koneksa enhances the accuracy and breadth of data that researchers can analyze, thereby minimizing subjective biases in clinical endpoints. Additionally, the platform provides a dashboard that offers electronic clinical outcome assessments and reminders for study participants. Established in 2013 and headquartered in New York, Koneksa also maintains a presence in London, United Kingdom, and is recognized for its contributions to improving the efficiency of drug development through innovative data analysis.

Volansi, Inc. is a logistics and transportation company specializing in the manufacture of heavy-payload drones designed for commercial, defense, and humanitarian use. Founded in 2015 and headquartered in Concord, California, Volansi develops autonomous aerial delivery systems that enable time-critical shipments over long distances. The company's unmanned aerial vehicles are utilized across various industries, including construction, oil and gas, mining, and healthcare, providing on-demand and point-to-point delivery solutions. By focusing on fixed routes, Volansi addresses specific logistical challenges related to time and cost, enhancing the efficiency of goods delivery for enterprise customers.

Seagen is a clinical-stage biotechnology company based in Bothell, Washington, that specializes in developing and commercializing monoclonal antibody-based therapies for cancer and autoimmune diseases. Founded in 1997, the company focuses on creating innovative cancer therapies, particularly antibody-drug conjugates, to treat various malignancies, including Hodgkin lymphoma, non-Hodgkin lymphoma, urothelial cancer, and breast cancer. Its lead product, SGN-35, is undergoing pivotal trials for relapsed or refractory Hodgkin lymphoma. In addition to SGN-35, Seagen is advancing several other product candidates through various stages of clinical trials, including SGN-40, SGN-33, SGN-70, and SGN-75. The company has established collaborations with several prominent pharmaceutical firms, enhancing its research capabilities and drug development efforts. Through its commitment to innovative cancer therapies, Seagen aims to improve treatment outcomes for patients with diverse types of cancer.

AeroSafe Global is a U.S.-based company that develops and manufactures aerogels for thermal insulation, primarily serving the biopharmaceutical industry. Its products ensure reliable, sustainable, and simple temperature-sensitive supply chain solutions. AeroSafe Global specializes in cold-chain services, providing customized packaging, logistics, and operational services to prevent any temperature excursions during transportation of biomedical and pharmaceutical products.

Zapata Computing, Inc. is a quantum software company that specializes in developing innovative computing solutions tailored for industrial and commercial applications. Founded in 2017 and headquartered in Boston, Massachusetts, with an additional office in Toronto, the company emerged from Harvard University and is driven by a team of scientists, including Alán Aspuru-Guzik. Zapata offers Orquestra, a software platform that enables the composition of quantum workflows using a YAML-compatible language, facilitating tasks across both quantum and classical hardware. Its solutions are hardware-agnostic and cater to various sectors, including finance, healthcare, pharmaceuticals, transportation, logistics, energy, and more. Equipped to address complex challenges, Zapata Computing focuses on simulation, optimization, and machine learning, helping enterprise organizations harness the power of quantum technology to enhance their operations.

Tasso, Inc., established in 2012 and based in Seattle, Washington, specializes in manufacturing clinical-grade, at-home blood sample collection devices. Their innovative product allows patients to conveniently and painlessly collect their own blood at home using a simple, push-button mechanism, and then mail the samples to a qualified lab for analysis. This approach aims to enhance accessibility and comfort in blood-based diagnostics, reducing the need for clinic visits.

SAB Biotherapeutics is a clinical-stage biopharmaceutical company established in 2014, headquartered in Sioux Falls, South Dakota with additional offices in Cambridge, Massachusetts. The company specializes in developing immunotherapies using its proprietary DiversitAb platform, which employs transchromosomic cattle to produce large quantities of targeted human polyclonal antibodies without relying on human plasma or serum. SAB's pipeline includes therapies for conditions such as Type 1 diabetes (SAB-142), seasonal influenza (SAB-176), and Middle East Respiratory Syndrome Coronavirus (MERS-CoV, SAB-301).

Preventice Solutions, Inc., established in 2007, specializes in healthcare technology solutions. The company offers a range of services, sensors, and software to remotely monitor and manage patient health data, primarily focusing on cardiac care. Key products include the PatientCare Portal, a self-managed cloud platform for real-time patient data management; BodyGuardian Heart, a pocket-sized wearable monitor for enhanced patient mobility and compliance; and BodyGuardian Verité, a dual-modality remote cardiac sensor for physicians. Preventice Solutions operates from Eagan, Minnesota, with additional offices in Fargo, North Dakota, San Francisco, California, and Houston, Texas.

Syapse, Inc. is a technology company that specializes in precision medicine through its innovative software platform, which aggregates and analyzes clinical, molecular, treatment, and outcomes data. Founded in 2008 and headquartered in San Francisco, California, with an additional office in Radnor, Pennsylvania, Syapse aims to enhance healthcare by providing actionable insights that support data-driven decision-making in precision oncology. The company operates the Syapse Learning Health Network, a global network that enables health systems and life sciences collaborators to share real-world cancer data. This network empowers healthcare organizations to collaborate effectively, ensuring that oncologists and decision-makers have access to comprehensive patient insights at the point of care, ultimately driving improved outcomes for cancer patients. Syapse has established strategic partnerships, including a collaboration with Pfizer, to further its mission of delivering personalized care based on robust real-world evidence.

Themis Bioscience N.V. is a clinical-stage biopharmaceutical company headquartered in Vienna, Austria, specializing in immunomodulation to develop products aimed at protecting against infectious diseases. Founded in 2009, the company’s lead product candidate, MV-CHIK, has completed Phase II clinical trials for chikungunya treatment. Themis is also engaged in developing vaccines for various health threats, including cancer, Zika virus, Lassa fever, and MERS. Themis leverages its advanced understanding of immune system mechanisms through its innovative vaccine platform, focusing on both emerging and specialized indications. The company has established research collaborations and exclusive licensing agreements to enhance its development capabilities, positioning itself as a strategic partner for leading biotechnology and pharmaceutical firms.

Ayogo Health Inc., established in 2008 and headquartered in Vancouver, Canada, specializes in developing digital health solutions that engage patients and improve adherence to treatment plans for chronic conditions. The company's core products include GoodLife, a customizable platform combining gamification, incentives, and social features, and Alternate Reality Games, which blend online and real-world elements for educational purposes. Ayogo serves clients such as insurers, healthcare providers, and pharmaceutical companies by applying behavioral psychology and social gaming principles to enhance patient outcomes. The company's collaborative approach involves meaningful engagement with patients, end-users, and clients throughout project development.

ArQule, Inc. is a clinical-stage biopharmaceutical company focused on the research and development of targeted therapeutics for cancer and rare diseases. Founded in 1993 and headquartered in Burlington, Massachusetts, the company employs its ArQule Kinase Inhibitor Platform to design and develop novel small molecule drugs. ArQule's pipeline includes several investigational therapies, such as ARQ 531, a dual inhibitor of Bruton’s tyrosine kinase for B-cell malignancies; miransertib, an AKT inhibitor for advanced endometrial cancer; and ARQ 75, also targeting AKT in solid tumors. Additionally, Derazantinib is a multi-kinase inhibitor in clinical trials for intrahepatic cholangiocarcinoma. The company has established license agreements with Basilea Pharmaceutica and Roivant Sciences for its therapeutic candidates. As of January 2020, ArQule operates as a subsidiary of Merck Sharp & Dohme Corp.

Calporta is developing selective small molecule agonists of TRPML1 (transient receptor potential cation channel, mucolipin subfamily, member 1) for the treatment of Niemann-Pick C Disease (NPC) and other lysosomal storage diseases. Mutations that cause NPC lead to impaired intracellular lipid trafficking and lead to lysosomal accumulation of cholesterol and biolipds. TRPML1 is an ion channel in the lysosome and a key regulator of lysosomal trafficking processes. Impaired TRPML1 function has been implicated in multiple pathological conditions, including NPC. Agonists of TRPML1 restore calcium efflux and normalize lysosomal trafficking and function. In addition to NPC and other lysosomal storage diseases, agonists of TRPML1 may have broad potential in other diseases such as muscular dystrophy and various taopathies such as Alzheimer's disease. Calporta's approach is based on research from the lab of Haoxing Xu, Ph.D., at the University of Michigan.

PathAI, Inc. is a technology company that specializes in developing artificial intelligence solutions for pathology laboratories. Founded in 2016 and headquartered in Boston, Massachusetts, with an additional office in Austin, Texas, PathAI focuses on enhancing the accuracy and efficiency of cancer diagnosis and treatment. The company's platform employs machine and deep learning techniques to analyze large datasets, assisting pathologists in making rapid and precise diagnoses for patients. By addressing complex challenges in pathology, PathAI aims to facilitate personalized medicine and improve patient outcomes by identifying individuals who may benefit from innovative therapies.

She's Well is a fertility management company that offers a subscription-based model designed to assist individuals and couples in starting families at their own pace. By collaborating with a network of leading fertility centers, the company provides financing options for various fertility services, including testing, in vitro fertilization (IVF), egg freezing, and sperm freezing. She’s Well adopts an on-demand concierge care approach, offering personalized support and guidance to navigate the complexities of fertility treatment. Recognizing that infertility affects one in six couples and that many individuals are delaying childbirth, the company aims to make fertility care more accessible and affordable, addressing a significant gap in the market where traditional health plans often lack coverage for such services. With typical IVF costs ranging from $12,000 to $20,000 and additional expenses for genetic testing, She's Well's subscription plans seek to alleviate the financial burden and empower individuals to make family planning decisions without the constraints of biological timelines.

Themis Bioscience N.V. is a clinical-stage biopharmaceutical company headquartered in Vienna, Austria, specializing in immunomodulation to develop products aimed at protecting against infectious diseases. Founded in 2009, the company’s lead product candidate, MV-CHIK, has completed Phase II clinical trials for chikungunya treatment. Themis is also engaged in developing vaccines for various health threats, including cancer, Zika virus, Lassa fever, and MERS. Themis leverages its advanced understanding of immune system mechanisms through its innovative vaccine platform, focusing on both emerging and specialized indications. The company has established research collaborations and exclusive licensing agreements to enhance its development capabilities, positioning itself as a strategic partner for leading biotechnology and pharmaceutical firms.

Navigating Cancer, Inc., established in 2008 and headquartered in Seattle, Washington, operates a Web-based patient care portal designed specifically for cancer programs. This platform enables cancer survivors to receive, organize, and understand their medical information, track their health, and engage with healthcare professionals. It also offers educational resources on various types of cancer and chemotherapy treatments. The portal aims to simplify practice workflows for healthcare providers, facilitate patient-centered care, and improve overall outcomes by empowering patients through technology.

CIOX Health, LLC is a healthcare technology company that operates a platform designed to manage and share patient medical records securely. Established in 1976, the company offers services such as information release, denials prevention, coding and education, imaging, clinical abstraction, oncology data management, medical record retrieval, second level review coding, risk adjustment solutions, and AudaPro, an audit tool for centralizing processes. Serving healthcare providers, health plans, real-world data companies, government agencies, law firms, life insurance companies, and patients, CIOX aims to improve healthcare outcomes by transforming shared information into actionable insights. As of 2021, the company operates as a subsidiary of CT Technologies Holdings, LLC following its merger with Datavant.

Tilos Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative antibody therapeutics aimed at treating cancer, fibrosis, and related disorders. Founded in 2016 and based in Cambridge, Massachusetts, the company specializes in antibodies that target the Latency Associated Peptide of TGF beta, which plays a crucial role in regulating immune responses. Tilos Therapeutics is particularly focused on the modulation of regulatory T cells and effector cell regulation, leveraging the immune system to create effective therapies. By enhancing treatment options, Tilos aims to enable patients to begin their therapies more swiftly, ultimately leading to improved medical outcomes. As of mid-2019, Tilos operates as a subsidiary of Merck & Co., Inc.

Mesentech Inc. is a regenerative medicine company based in Vancouver, Canada, focused on developing innovative therapies for bone-related diseases. Established in 2013, the company specializes in a prodrug platform that delivers therapeutics selectively to bone, addressing challenges associated with conventional drug delivery methods. Mesentech's lead product, MES1007, is a bone-targeted prodrug of a prostaglandin mimetic that aims to reverse bone loss associated with conditions such as osteoporosis and Duchenne muscular dystrophy. The company's proprietary technology enhances the delivery of small-molecule and biological drugs to the bone's surface and interior, allowing for more effective treatment while minimizing side effects. This approach is particularly significant given the inherent difficulty in accessing bone tissue due to its hard surface and low porosity. Mesentech's focus on selective drug delivery not only aims to improve treatment efficacy but also hopes to accelerate bone healing and address complications associated with low bone density disorders.

Peloton Therapeutics, Inc. is a clinical stage biopharmaceutical company based in Dallas, Texas, dedicated to developing innovative medicines for patients with cancer and other serious conditions. The company focuses on targeting HIF-2a, a transcription factor previously considered difficult to address with small molecules. Its lead drug candidate, PT2977, is an oral HIF-2a inhibitor currently undergoing Phase 2 clinical trials for advanced or metastatic clear cell renal cell carcinoma, and it is being evaluated in various settings, including in patients with von Hippel-Lindau disease-associated renal cell carcinoma and in combination with cabozantinib. Additionally, Peloton is advancing PT2567, another oral HIF-2a inhibitor in preclinical development for non-oncology indications such as pulmonary arterial hypertension. Founded in 2010 and previously known as Damascus Pharmaceutics, Peloton Therapeutics aims to leverage its scientific expertise and collaborations to become a leading biotech company in the region.

ConnectedMed builds digital therapeutics platform that allows patients to manage their primary and chronic care needs.

Navigating Cancer, Inc., established in 2008 and headquartered in Seattle, Washington, operates a Web-based patient care portal designed specifically for cancer programs. This platform enables cancer survivors to receive, organize, and understand their medical information, track their health, and engage with healthcare professionals. It also offers educational resources on various types of cancer and chemotherapy treatments. The portal aims to simplify practice workflows for healthcare providers, facilitate patient-centered care, and improve overall outcomes by empowering patients through technology.

TriNetX, Inc. operates a global health research network that facilitates clinical research and enhances the discovery of new therapies. The company provides a suite of tools, including TriNetX Live for analyzing patient populations, TriNetX Research for accessing longitudinal clinical data, and TriNetX Download for obtaining real-world clinical data through a unified platform. Additionally, TriNetX offers Attract Trials to streamline collaboration, Natural Language Processing to extract clinical information from physician notes, and specialized oncology solutions to link researchers with clinical and genomic data. Serving healthcare organizations, biopharmaceutical companies, and contract research organizations, TriNetX aims to optimize clinical trial design and recruitment, improving the speed and efficiency of bringing new therapies to market. Established in 2013, the company is headquartered in Cambridge, Massachusetts, with additional offices in Sydney, London, and Sao Paulo.

Clinithink Ltd is a UK-based healthcare software company that specializes in cloud-based data analytics solutions. Founded in 2009 and led by CEO Chris Tackaberry, Clinithink has developed innovative technologies, including its Clinical Language Indexing software (CLiX), which utilizes Natural Language Processing to transform unstructured clinical narratives into structured data. Its products, such as CLiX ENRICH, facilitate the collection and indexing of clinical trial data while allowing users to document information in their preferred narrative style. Additionally, Clinithink offers CLiX RARE, designed to assist in diagnosing genetic disorders in newborns. The company serves a diverse clientele, including healthcare providers, pharmaceutical companies, and content vendors, aiming to enhance data accessibility and improve decision-making within the healthcare sector.

Immune Design Corp., a clinical-stage immunotherapy company based in Seattle, Washington, focuses on enabling the body's immune system to combat diseases, with a primary emphasis on cancer treatment. The company leverages its ZVex and GLAAS discovery platforms to develop innovative therapies. Its lead product candidate is G100, currently in Phase II clinical trials for treating follicular non-Hodgkin lymphoma, both as a monotherapy and in combination therapy. Immune Design has collaboration and license agreements with Sanofi Pasteur. The company was founded in 2008 and operates under the umbrella of Merck & Co., Inc.

Kytopen, established in 2017 and based in Cambridge, Massachusetts, specializes in the development of a cell therapy platform. This platform facilitates the non-viral delivery of molecules into challenging-to-transfect immune cells, making the process easier, faster, and more cost-effective. The company's proprietary Flowfect™ technology combines microfluidics and automation, enabling researchers to explore new biological discoveries and develop more affordable cell and gene therapies.

Antelliq is a leading provider of animal intelligence solutions, specializing in the design, manufacture, and distribution of products aimed at improving the management, health, and well-being of livestock, pets, and fish. The company offers a range of digital identification, traceability, and monitoring solutions that serve veterinarians, farmers, and pet owners worldwide. Operating under well-known brands such as Allflex, Sure Petcare, and Biomark, Antelliq delivers smart devices and data analytics that enhance understanding of animal activity and health needs. With over 1,900 employees and a presence in more than 100 countries, Antelliq supports various sectors, including agriculture and conservation, through innovative technologies developed at its four global Innovation Centers. These centers focus on areas such as multi-disciplinary monitoring, electronic identification, and connected devices, leveraging decades of research and development to create cutting-edge solutions for animal care. Founded in 2013 and based in Vitré, France, Antelliq became a subsidiary of Merck Animal Health in April 2019.

ClearDATA Networks, Inc. specializes in providing cloud computing and information security solutions tailored for the healthcare sector, serving healthcare providers, life sciences organizations, and payers. Established in 2009 and headquartered in Austin, Texas, the company offers a comprehensive multi-cloud platform that automates, protects, and manages healthcare applications and data. Its key products include ClearDATA Comply, a software solution for maintaining healthcare cloud compliance, and ClearDATA Assess, which aids in conducting mandatory HIPAA Security Risk Assessments. Additionally, ClearDATA Locate Mask allows organizations to utilize unstructured datasets while safeguarding sensitive information. The company is recognized for its HITRUST-certified cloud services, which ensure robust data privacy protections and extensive compliance capabilities, helping healthcare organizations leverage data effectively while enhancing operational efficiency.

Artios Pharma Limited is a biotechnology company based in Cambridge, United Kingdom, that specializes in developing innovative cancer treatments targeting DNA damage response (DDR) pathways. Founded in 2016, the company is dedicated to creating first-in-class therapies that selectively kill cancer cells by exploiting their reliance on DDR mechanisms. Artios’ product pipeline includes a range of promising candidates, such as a therapy that targets DNA polymerase theta, a protein involved in DNA repair processes, and another program focusing on a novel DDR target. The company collaborates with prominent research organizations, including Cancer Research Technology, to enhance its development efforts and leverage expertise in DNA repair. Artios is led by a skilled team with extensive experience in drug discovery, positioning it to advance its next-generation DDR programs and contribute significantly to the field of cancer treatment.

Sutro Biopharma, Inc. is a clinical-stage drug discovery, development, and manufacturing company based in South San Francisco, California. The company specializes in creating next-generation protein therapeutics for cancer and autoimmune disorders using its proprietary integrated cell-free protein synthesis platform known as XpressCF. Sutro Biopharma’s product candidates include STRO-001, an antibody-drug conjugate targeting CD74 for patients with multiple myeloma and non-Hodgkin lymphoma, and STRO-002, an antibody-drug conjugate directed against folate receptor-alpha for treating ovarian and endometrial cancers. The company has also established collaboration and licensing agreements to advance bispecific antibodies and antibody-drug conjugates primarily in the field of immuno-oncology. Founded in 2003, Sutro Biopharma is dedicated to developing innovative biopharmaceutical solutions.

Strata Oncology, Inc. is a precision oncology company focused on enhancing cancer care by facilitating access to precision medicine clinical trials and expediting drug approval processes. Based in Ann Arbor, Michigan, the company develops a comprehensive precision oncology platform that supports routine testing and efficient use of molecular data. Strata's offerings include The Strata Trial, a genomic testing program for systematic precision oncology implementation, and StrataNGS, a targeted assay for sequencing DNA and RNA from biopsies. Additionally, StrataPOINT integrates electronic medical record histories with molecular profiling to ensure eligible patients are tested and considered for trial enrollment. The company features a portfolio of pharma-sponsored therapeutic protocols, known as Strata Partnered Trials, aligned to specific biomarkers. Strata also operates The Strata Lab, a cancer sequencing facility, and maintains the Strata Precision Oncology Network, a collaborative entity aimed at promoting precision medicine initiatives. Formerly known as Strata Oncology Research, Inc., the company rebranded in 2016 and has been incorporated since 2015.

Pelago, formerly known as Quit Genius, is a leading virtual clinic focused on substance use management, specializing in support for individuals struggling with addictions to tobacco, alcohol, and opioids. The company provides a comprehensive approach to substance use support, offering education, management skills, and opportunities for positive change. Pelago's platform utilizes cognitive behavioral therapy (CBT) and medication-assisted treatment (MAT) to deliver accessible and effective support tailored to individual needs. This service is designed to integrate seamlessly with health plans, pharmacy benefit managers, and wellness platforms, enabling employers to offer on-demand, personalized assistance to employees seeking healthier lifestyles. To date, Pelago has successfully assisted over 750,000 members in managing their substance use and improving their overall well-being. The platform features engaging resources such as animated videos, interactive exercises, and audio sessions, empowering users to confront their addictions in a personalized manner with the guidance of a coach.

Livongo Health, Inc. is a consumer digital health company that specializes in providing an integrated suite of solutions for individuals managing chronic conditions, particularly diabetes. Established in 2008 and headquartered in Mountain View, California, Livongo utilizes real-time data capture and analytics to promote health behavior change through its platform, which includes cellular-connected devices, supplies, coaching, and insights driven by data science. Its product offerings encompass Livongo for diabetes, hypertension, prediabetes and weight management, and behavioral health through its myStrength platform. The company serves a diverse client base, including employers, health plans, government entities, and labor unions, primarily within the United States. Livongo aims to enhance the experience of individuals with chronic conditions by providing timely, personalized support and information, ultimately leading to improved health outcomes. In 2020, Livongo became a subsidiary of Teladoc Health, Inc.

Viralytics Limited is a biotechnology company based in Sydney, Australia, specializing in the development and commercialization of oncolytic immunotherapies for cancer treatment. The company’s lead product, CAVATAK, is a proprietary formulation of a common cold virus that is currently undergoing Phase Ib and Phase II clinical trials for various cancers, including melanoma, lung, and bladder cancer. In addition to CAVATAK, Viralytics is developing EVATAK, aimed at treating ovarian, prostate, and gastric cancers. The company leverages the cancer-targeting properties of benign viruses to enhance the efficacy of cancer therapies while minimizing side effects. Formerly known as Psiron Ltd., Viralytics rebranded in December 2006 and has operations in Newcastle, Australia. As of June 2018, Viralytics is a subsidiary of Merck & Co. Inc.

electroCore, Inc. is a commercial stage medical device company based in Basking Ridge, New Jersey, specializing in bioelectronic medicine. The company focuses on the development and commercialization of non-invasive vagus nerve stimulation (nVNS) therapies, primarily aimed at enhancing patient outcomes in neurology. Its flagship product, gammaCore, is a prescription-only device designed for the acute treatment of pain associated with migraine and episodic cluster headaches, as well as for the preventive treatment of these conditions in adult patients. The gammaCore Sapphire is a rechargeable and reloadable handheld system that can be prescribed on a monthly basis for multi-year use. Founded in 2005, electroCore aims to address various neurological conditions through its innovative therapeutic platform.

Prognos Health is a health tech company focused on healthcare analytics, offering a platform called prognosFACTOR. This innovative platform can quickly query billions of lab and health records from over 325 million de-identified patients, providing answers to clinically relevant healthcare questions in a fraction of the time traditionally required. Prognos Health allows clients to access HIPAA-compliant, patient-centric healthcare data through the Prognos Marketplace, facilitating a range of applications such as cohort design, patient journey studies, and health outcomes analysis. The company's clientele includes 25 of the top 30 pharmaceutical manufacturers and three of the top five health payers, highlighting its significant role in empowering precise decision-making throughout the healthcare landscape.

Syapse, Inc. is a technology company that specializes in precision medicine through its innovative software platform, which aggregates and analyzes clinical, molecular, treatment, and outcomes data. Founded in 2008 and headquartered in San Francisco, California, with an additional office in Radnor, Pennsylvania, Syapse aims to enhance healthcare by providing actionable insights that support data-driven decision-making in precision oncology. The company operates the Syapse Learning Health Network, a global network that enables health systems and life sciences collaborators to share real-world cancer data. This network empowers healthcare organizations to collaborate effectively, ensuring that oncologists and decision-makers have access to comprehensive patient insights at the point of care, ultimately driving improved outcomes for cancer patients. Syapse has established strategic partnerships, including a collaboration with Pfizer, to further its mission of delivering personalized care based on robust real-world evidence.

PatientSafe Solutions, headquartered in San Diego, California, specializes in smart point-of-care mobile solutions aimed at transforming healthcare delivery. Its flagship product, the PatientTouch System, enhances care team productivity and patient safety by consolidating clinical workflows into a single, portable device. The innovative platform integrates communication, workflow management, and real-time access to electronic medical records, facilitating effective collaboration among clinicians. Features such as Positive Patient Identification, customizable care interventions, and real-time alerting capabilities support critical processes like medication administration and specimen collection. By leveraging advanced technology, PatientSafe Solutions enables healthcare providers to improve safety, increase efficiency, and reduce operational costs, positioning itself as a leader in accountable care innovation.

LifeMine Therapeutics, Inc. is a biotechnology company focused on the genomic discovery of new drug modalities derived from eukaryotic microbes, specifically fungi. Founded in 2016 and headquartered in Cambridge, Massachusetts, with an additional office in New York, it employs an integrated drug discovery platform that combines genomics, artificial intelligence, and synthetic biology. LifeMine’s Avatar-Rx platform utilizes high-throughput microbiology, data science, genome engineering, and automation technologies to identify novel gene-encoded molecules (GEMs) with specific biological functions. The company emphasizes chemoinformatic-assisted drug optimization and advanced chemical synthesis, enabling the progression of new product candidates into development. Founded by experts in the field, LifeMine Therapeutics aims to innovate medicine through its unique approach to leveraging the fungal biosphere.

Antidote is a digital health company focused on accelerating and improving medical research. By combining proprietary technologies, data, and well-established business models, the company is transforming the way patients and researchers connect so that breakthroughs happen faster. Antidote was launched as TrialReach in 2010 and rebranded to Antidote in 2016. The company is based in the US and the UK.

Rigontec GmbH is a biopharmaceutical company based in Planegg, Germany, focused on developing RNA-based immunotherapeutics for cancer and viral diseases. Founded in 2014, the company is recognized for its innovative approach to immuno-oncology, particularly through its lead compound ImOl100. This compound acts as a stimulator of the immune receptor retinoic acid-inducible gene I (RIG-I), which detects viral RNA and promotes immune responses. ImOl100 serves as a minimal mimic of naturally occurring 3pRNA, a motif commonly found in viral RNAs, and aims to overcome the limitations associated with traditional cancer vaccines and checkpoint inhibitors. As of October 2017, Rigontec operates as a subsidiary of Merck & Co., enhancing its capabilities in the development of effective therapeutic options for patients.

Serimmune Inc. is a biotechnology company based in Goleta, California, focused on developing diagnostics and therapeutics for autoimmune diseases. Founded in 2014, the company utilizes a universal serology platform that incorporates bacterial display peptide libraries, sequencing, and machine learning to analyze immune responses. Through its serum epitope repertoire analysis (SERA) technology, Serimmune can identify a diverse array of antigens that stimulate immunity, mapping specific antibodies to various diseases, including infections, allergies, autoimmune disorders, and cancers. This innovative approach allows for comprehensive profiling of antibody repertoires in a single assay, ultimately aiding medical practitioners in the diagnosis and treatment of various health conditions.

ClearDATA Networks, Inc. specializes in providing cloud computing and information security solutions tailored for the healthcare sector, serving healthcare providers, life sciences organizations, and payers. Established in 2009 and headquartered in Austin, Texas, the company offers a comprehensive multi-cloud platform that automates, protects, and manages healthcare applications and data. Its key products include ClearDATA Comply, a software solution for maintaining healthcare cloud compliance, and ClearDATA Assess, which aids in conducting mandatory HIPAA Security Risk Assessments. Additionally, ClearDATA Locate Mask allows organizations to utilize unstructured datasets while safeguarding sensitive information. The company is recognized for its HITRUST-certified cloud services, which ensure robust data privacy protections and extensive compliance capabilities, helping healthcare organizations leverage data effectively while enhancing operational efficiency.

Livongo Health, Inc. is a consumer digital health company that specializes in providing an integrated suite of solutions for individuals managing chronic conditions, particularly diabetes. Established in 2008 and headquartered in Mountain View, California, Livongo utilizes real-time data capture and analytics to promote health behavior change through its platform, which includes cellular-connected devices, supplies, coaching, and insights driven by data science. Its product offerings encompass Livongo for diabetes, hypertension, prediabetes and weight management, and behavioral health through its myStrength platform. The company serves a diverse client base, including employers, health plans, government entities, and labor unions, primarily within the United States. Livongo aims to enhance the experience of individuals with chronic conditions by providing timely, personalized support and information, ultimately leading to improved health outcomes. In 2020, Livongo became a subsidiary of Teladoc Health, Inc.

Arcadia Solutions, LLC is a healthcare technology company based in Burlington, Massachusetts, specializing in electronic health record (EHR) data aggregation and analytics. Founded in 2002, Arcadia provides a suite of services and proprietary software aimed at large healthcare providers, payors, accountable care organizations, and health information exchanges. The company offers various IT services, including EHR implementation and optimization, performance management, and information security solutions. Additionally, Arcadia develops customizable tools for planning and maintaining health IT infrastructures, which include monitoring services to evaluate key performance indicators and manage technology lifecycle needs. By integrating diverse healthcare data into a unified platform, Arcadia enables organizations to derive actionable insights that enhance care, support research, and drive strategic growth while ensuring financial success.